Loading...
•
Sep 30, 2024
OptimizeRx Q3 2024 Earnings Report
OptimizeRx's Q3 2024 performance saw revenue under expectations but met adjusted EBITDA targets, reflecting business scale and leverage.
Key Takeaways
OptimizeRx reported Q3 2024 financial results with revenue of $21.3 million, a 30% increase year-over-year. The company's gross profit increased by 37% to $13.4 million, with a gross margin of 63%. They also won 5 DAAP deals during the quarter and paid down $2.0 million of their term loan.
Q3 revenue reached $21.3 million, a 30% increase year-over-year.
Gross profit increased by 37% year-over-year, reaching $13.4 million with a 63% gross margin.
The company secured 5 DAAP deals during Q3.
An additional $2.0 million of principal was paid down on the term loan since the end of Q3, with positive cash flow for the period.
Forward Guidance
OptimizeRx updated its 2024 guidance and expects revenue to be between $88 million and $92 million with an Adjusted EBITDA to be between $8 million and $10 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...